Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies

Systematic Review of Pharmacogenetic Factors That Influence High-Dose Methotrexate Pharmacokinetics in Pediatric Malignancies

Methotrexate (MTX) is a mainstay therapeutic agent administered at high doses for the treatment of pediatric and adult malignancies, such as acute lymphoblastic leukemia, osteosarcoma, and lymphoma. Despite the vast evidence for clinical efficacy, high-dose MTX displays significant inter-individual...

Full description

Bibliographic Details
Main Authors: Zachary L. Taylor, Jesper Vang, Elixabet Lopez-Lopez, Natanja Oosterom, Torben Mikkelsen, Laura B. Ramsey
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
methotrexate
pharmacokinetics
pharmacogenetics
pediatrics
acute lymphoblastic leukemia
osteosarcoma
Online Access:https://www.mdpi.com/2072-6694/13/11/2837

Similar Items

Similar Items